Dead Cat Bounce, Or is a Sustainable Relief Rally in Store for Valeant (VRX)?

Valeant Pharma (VRX) Adds to Gains

Beaten down Valeant Pharma (NYSE: VRX) is adding to yesterday's gains in pre-open trade. Shares are up 5.8% to $106.28 after rising 7.15% yesterday. Shares have been under extreme pressure as short sellers point to fraud at the company and regulators point to 'price... More

Bill Ackman's Pershing Square Down 19% YTD (VRX)

Bill Ackman's Pershing Square Holdings, Ltd. released its regular monthly Net Asset Value (NAV) and Performance Report for the month of October 2015. Data showed the fund was down 7.3% during the month and is now down 19% on the year.

Much of the weakness is tied to the hedge fund's oversized... More

Valeant Pharma (VRX) Issues Dear Doctor Letter; Philidor Issues Release - Evercore ISI

Evercore ISI analyst Umer Raffat noted two new developments in the Valeant Pharma (NYSE: VRX) saga. First the company sent a dear doctor letter to dermatologists and separately, Philidor issued a press release.

Raffat highlighted the following from the letter:

Valeant Pharma (VRX) Was Top Stock for TD Ameritrade Retail Clients on Friday - Sherrod

Valeant Pharma (NYSE: VRX) was the most heavily traded stock for TD Ameritrade retail investors on Friday, Nicole Sherrod said. Buys heavily outweighed sells.

$VRX was the #1 top traded stock for TD Ameritrade retail investors on Friday. Buys heavily outweighing sells.

Goldman Sachs says Valeant has long road ahead, cuts rating

By Ankur Banerjee

(Reuters) - Goldman Sachs on Monday downgraded Valeant Pharmaceuticals International Inc's (NYSE: VRX) (NYSE: VRX) stock, nearly two weeks after an influential short seller accused the Canadian drug maker of cooking its books.

While investors have fled the company's stock, which has lost a third of its value since Citron Research published its report on Oct. 21, sell-side analysts have remained stubbornly positive on the stock.

BTIG and BMO Capital Markets have lowered their ratings to "hold" in the past two weeks.... More

Citron's Andrew Left said he is not done with Valeant (VRX) story; Will pass info to main stream media

Citron's Andrew Left said he is not done with Valeant (NYSE: VRX) story. Will pass info to main stream media.

Citron's Andrew Left denies he made $150 million short Valeant (VRX)

Citron's Andrew Left denies he made $150 million short Valeant (NYSE: VRX).

Citron's Left stands by story on Valeant (VRX)

Citron's Left stands by story on Valeant (NYSE: VRX)

Citron's Left said "I have nothing with Bill Ackman. This is about Valeant (VRX)"

Citron's Left said "I have nothing with Bill Ackman. This is about Valeant (NYSE: VRX)."

Citron's Left said he was not contacted by the SEC on Valeant Pharma (VRX) over the weekend

Citron's Left said he was not contacted by the SEC on Valeant Pharma (NYSE: VRX) over the weekend.

Valeant Pharma (VRX) story 'taken on a life of its own" - Citron's Left

Valeant Pharma (NYSE: VRX) story 'taken on a life of its own" - Citron's Left

Valeant Pharma (VRX) on Watch Ahead of Citron Left Interview

Bouncing 8% in early trade after Citron Research dialed back on the explosiveness of its report, Valeant Pharma (NYSE: VRX) is on watch ahead of Citron's Andrew Left interview on CNBC at 12PM ET.

Left... More

Citron publishes no new allegations against Valeant, shares rise

NEW YORK (Reuters) - Influential short-selling firm Citron Research did not publish new allegations against Valeant Pharmaceuticals International Inc (NYSE: VRX) on Monday as many investors had anticipated, giving the beleaguered shares of the Canadian drugmaker a boost.

Citron had promised in a tweet on Friday to "update" the story on Monday, following on from its scathing report in October that alleged accounting improprieties in a network of specialty pharmacies, including Philidor Rx, that Valeant used to distribute its drugs. (https://twitter.com/CitronResearch)

"Valeants operation is far 'dirtier' than just... More

Citron Updates Report on Valeant Pharma (VRX), Not Dialing Back Warning

Citron said in an updated report that it isn't dialing back its warning on Valeant Pharma (NYSE: VRX).

Citron Research: Not Dialing Back Warning on Valeant Pharma (VRX), Dialing Back on Citron Focus

(Updated - November 2, 2015 10:06 AM EST)

Citron Research: Not dialing back warning on Valeant Pharma (NYSE: VRX), instead they are dialing back the focus on Citron to investigate and report the vast spectrum of claims now piling up against the company.

Citron said "For those of you expecting a kill shot, you can stop reading here."

Citron said the stock is uninvestible for the foreseeable future.

Citron provided the following list of some but not all of the immediate concerns facing Valeant and its shareholders:

1) Valeants civil and criminal culpability... More

Valeant Pharma (VRX) Ticks Higher as Short Seller Softens Further Allegations

Valeant Pharmaceuticals (NYSE: VRX) shares are ticking higher Monday as one pundit on the stock opted to back off from issuing fierce commentary about the company's operations.

As... More

Wall St. climbs, led by energy, healthcare; Nasdaq 100 hits 15-year high

By Lewis Krauskopf

(Reuters) - U.S. stocks added to their recent run with gains across all sectors on Monday, led by increases in the beaten-down energy group and the acquisition-driven healthcare industry.

The gains on the first trading day of the month followed the best monthly performance of the major indexes in four years in October. The Nasdaq 100 on Monday closed at its highest level in more than 15 years.

Data on Monday showed U.S. manufacturing activity in October sank to a 2-1/2-year low, but a rise in new orders offered encouragement. Elsewhere,... More

Valeant Pharmaceuticals (VRX) PT, Estimates Cut at Jefferies after Dropping Philidor

Jefferies analyst David Steinberg lowered estimates and his price target on Valeant Pharmaceuticals (NYSE: VRX) to $172.00 (from $224.00) after the company dropped Philidor but maintained a Buy rating.

commented, "VRX severed ties with Philidor following allegations of improper business conduct and intense... More

Goldman Sachs Downgrades Valeant Pharmaceuticals (VRX) to Neutral

(Updated - November 2, 2015 8:42 AM EST)

Goldman Sachs downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Neutral with a price target of $122 (prior $180). Analyst Gary Nachman thinks re-establishing confidence will be a long road.

"Given the events that have transpired very rapidly in recent weeks... More

Citron Research: Don't Expect Anything Earth-Shattering on Valeant (VRX) Come Monday

Citron Research's Andrew Left is dialing back on what investors should expect when he updates his report on battered Valeant Pharma (NYSE: VRX) on Monday.

During Bill Ackman's 4-hour defense of Valeant on Friday, short seller Left tweeted: "$VRX has a... More